Tempus AI's stock surged 60%, fueled by a 31% year-over-year increase in oncology testing volumes and nearly doubled MRD test volumes since Q4 2025, validating its acquisition of Personalis. The company's data and applications segment grew 28% in Q2, driven by strong bookings and AI innovation, positioning Tempus for sustained growth and improved profit margins. Despite a high valuation, Tempus's expanding clinical scope, self-reinforcing data cycle, and improving profitability support a positive long-term outlook for investors.
As of Sep 22, 2026 10:51 WIB, Tempus AI (NASDAQ:TEM) trades at USD 78.05 on Pluang, showing a modest 1-day increase of 0.27%. The stock’s market cap stands at $14.13 billion, with a high buy interest of 99% among Pluang users. This strong buying activity highlights investor confidence in Tempus AI’s growth potential and expanding clinical applications.
Tempus AI's stock surged 29% in one week, driven by positive analyst commentary and new revenue prospects from reimbursement changes. Goldman Sachs initiated coverage with a Neutral rating and a $75 price target, while technical indicators like a tri...
Tempus AI shares surged nearly 30% this week following Morgan Stanley's optimistic revenue forecast driven by clearer reimbursement pricing for its diagnostic products. CEO Eric Lefkofsky highlighted potential revenue increases of $80-$100 million fr...
